Table 2

Patient characteristics in randomized trials of beta blockers for the prevention of sudden cardiac death
Trial (Reference) Mean age (Years) Male (%) Inclusion criteria Population (Ischaemic or non-ischaemic) Mean EF (%) NYHA
Anderson et al. 50 66 IDC Non-ischaemic 29 II-IV
ANZ13 67 80 chronic heart failure Ischaemic 29 II-III
BEST6 60 78 NYHA III-IV, EF ≤ 35% Both 23 III-IV
BHAT39 55 NR MI, HF NR NR NR
Bristow et al.14 55 61 IDC and ISCD Both 24 I-IV
Bristow et al.15 60 76 Mild, moderate, chronic heart failure Both 23 II-IV
CAPRICORN16 63 74 Acute MI, EF ≤ 40% Ischaemic 32 NR
CELICARD33 57 89.5 NYHA II- IV, LVEF<40% Both 26 II-III
CIBIS II18 61 80 NYHA III or IV, EF ≤ 35% Both 28 III-IV
CIBIS17 60 83 IDC, NYHA III-IV, ≤ 40% Both 25 III-IV
Colucci et al.19 54 85 Mildly symptomatic heart failure Both 23 II-III
COPERNICUS20 63.3 79.5 HF and EF ≤ 25% 67% ischaemic 20 NR
De Milliano et al.34 65 60 HF,, LVEF<35%, Both 25 II-III
ELANDD35 66 35 HF, age>40 years, LVEF>45% Non-ischaemic 62 II-III
Engleimeir et al.21 50 64 IDC Both 17 II-III
Fisher et al22 63 96 HF and CAD NR 23 II-IV
Hansteen V. et al.23 58 84.5 Acute MI NR NR NR
Krum et al.24 55 78 Advanced heart failure Both 16 II-IV
MDC25 49 73 DCM and EF<40% Non-ischaemic 22 I-III
MERIT-HF26 64 77 NYHA II-IV,EF ≤ 40% Both 28 II-IV
Metra et al.27 51 90 NYHA II-III, IDC Non-ischaemic 20 II-III
Olsen et al.28 52 94 NYHA II-III, IDC/CAD Both 20 II-IV
Packer et al.29 58 77 Chronic heart failure Both 23 II-IV
Pollock et al.30 54 79 CHF Both 21 II-IV
RESOLVD36 62 82 CHF(NYHA II- IV), LVEF<35% Both 28.5 I-IV
SENIORS11 76 63 HF,EF ≤ 35% NR 35 I-IV
Sturm et al.37 62 88 Age(18-75), LVEF≤25% Both 17 II-IV
UHLIR et al.38 56 89 Age(18-75), NYHA II- III, LVEF<40% Ischaemic NR II-III
Wisenbaugh et al.12 50 50 NYHA II-III, IDC/ISCD Both 24 II-III
Woodley et al.10 52 72 NYHA II- III, IDC/CAD Both 22 II-III

CAD Coronary artery disease, CHF congestive heart failure, DCM dilated cardiomyopathy, ISCD ischemic dilated cardiomyopathy, EF ejection fraction, HF Heart failure, IDC ischemic dilated cardiomyopathy, MDC Metoprolol in Dilated Cardiomyopathy, MI myocardial infarction, NR not reported, NYHA 'Classification of' New York Heart Association.

Al-Gobari et al.

Al-Gobari et al. BMC Cardiovascular Disorders 2013 13:52   doi:10.1186/1471-2261-13-52

Open Data